129 related articles for article (PubMed ID: 16231313)
41. RECIST revisited: a review of validation studies on tumour assessment.
Therasse P; Eisenhauer EA; Verweij J
Eur J Cancer; 2006 May; 42(8):1031-9. PubMed ID: 16616487
[TBL] [Abstract][Full Text] [Related]
42. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.
Trillet-Lenoir V; Freyer G; Kaemmerlen P; Fond A; Pellet O; Lombard-Bohas C; Gaudin JL; Lledo G; Mackiewicz R; Gouttebel MC; Moindrot H; Boyer JD; Chassignol L; Stremsdoerfer N; Desseigne F; Moreau JM; Hedelius F; Moraillon A; Chapuis F; Bleuse JP; Barbier Y; Heilmann MO; Valette PJ
Br J Radiol; 2002 Nov; 75(899):903-8. PubMed ID: 12466256
[TBL] [Abstract][Full Text] [Related]
43. Primary osteosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 22 cases with a review of the literature.
Gadwal SR; Gannon FH; Fanburg-Smith JC; Becoskie EM; Thompson LD
Cancer; 2001 Feb; 91(3):598-605. PubMed ID: 11169944
[TBL] [Abstract][Full Text] [Related]
44. Response evaluation criteria in solid tumors (RECIST): new guidelines.
Tsuchida Y; Therasse P
Med Pediatr Oncol; 2001 Jul; 37(1):1-3. PubMed ID: 11466715
[No Abstract] [Full Text] [Related]
45. Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer.
Jang GS; Kim MJ; Ha HI; Kim JH; Kim HS; Ju SB; Zang DY
Chin J Cancer Res; 2013 Dec; 25(6):689-94. PubMed ID: 24385696
[TBL] [Abstract][Full Text] [Related]
46. Recist and beyond.
Coche E
JBR-BTR; 2013; 96(3):167-71. PubMed ID: 23971174
[TBL] [Abstract][Full Text] [Related]
47. [Radiological response assessment of modern immunotherapy using iRECIST].
Persigehl T; Poeppel TD; Sedlaczek O
Radiologe; 2017 Oct; 57(10):826-833. PubMed ID: 28812098
[TBL] [Abstract][Full Text] [Related]
48. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.
Stacchiotti S; Collini P; Messina A; Morosi C; Barisella M; Bertulli R; Piovesan C; Dileo P; Torri V; Gronchi A; Casali PG
Radiology; 2009 May; 251(2):447-56. PubMed ID: 19261927
[TBL] [Abstract][Full Text] [Related]
49. A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors.
Lalchandani UR; Sahai V; Hersberger K; Francis IR; Wasnik AP
Curr Probl Diagn Radiol; 2019; 48(6):576-585. PubMed ID: 30181058
[TBL] [Abstract][Full Text] [Related]
50. Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations.
Siegel MJ; Ippolito JE; Wahl RL; Siegel BA
Radiol Imaging Cancer; 2023 Sep; 5(5):e230001. PubMed ID: 37540134
[TBL] [Abstract][Full Text] [Related]
51. Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer.
Yoshida S; Miyata Y; Ohtsu A; Boku N; Shirao K; Shimada Y
Gastric Cancer; 2000 Dec; 3(3):128-133. PubMed ID: 11984725
[TBL] [Abstract][Full Text] [Related]
52. RECIST measurements in cancer treatment: is there a role for physician assistants? - A pilot study.
Sailer AM; Douwes DC; Cappendijk VC; Bakers FC; Wagemans BA; Wildberger JE; Kessels AG; Beets-Tan RG
Cancer Imaging; 2014 Apr; 14(1):12. PubMed ID: 25608556
[TBL] [Abstract][Full Text] [Related]
53. Tool support to enable evaluation of the clinical response to treatment.
Levy MA; Rubin DL
AMIA Annu Symp Proc; 2008 Nov; 2008():399-403. PubMed ID: 18998923
[TBL] [Abstract][Full Text] [Related]
54. iRECIST: how to do it.
Persigehl T; Lennartz S; Schwartz LH
Cancer Imaging; 2020 Jan; 20(1):2. PubMed ID: 31900236
[TBL] [Abstract][Full Text] [Related]
55. Imaging endpoints for clinical trial use: a RECIST perspective.
Litière S; Bogaerts J
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36424032
[TBL] [Abstract][Full Text] [Related]
56. [Examination of tumor diameter measurement precision by RECIST].
Goto M; Ino K; Akahane M; Yamashita M; Suzuki Y; Imae T; Hasegawa H; Nishida K; Yano K; Iida K; Mima K; Ohtomo K
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2007 Jul; 63(7):774-81. PubMed ID: 17917339
[TBL] [Abstract][Full Text] [Related]
57. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline.
van Persijn van Meerten EL; Gelderblom H; Bloem JL
Eur Radiol; 2010 Jun; 20(6):1456-67. PubMed ID: 20033179
[TBL] [Abstract][Full Text] [Related]
58. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Seymour L; Bogaerts J; Perrone A; Ford R; Schwartz LH; Mandrekar S; Lin NU; Litière S; Dancey J; Chen A; Hodi FS; Therasse P; Hoekstra OS; Shankar LK; Wolchok JD; Ballinger M; Caramella C; de Vries EGE;
Lancet Oncol; 2017 Mar; 18(3):e143-e152. PubMed ID: 28271869
[TBL] [Abstract][Full Text] [Related]
59. Can paediatric radiologists resist RECIST (response evaluation criteria in solid tumours)?
McHugh K; Kao S
Pediatr Radiol; 2003 Nov; 33(11):739-43. PubMed ID: 14655676
[No Abstract] [Full Text] [Related]
60. RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
Iannessi A; Beaumont H; Liu Y; Bertrand AS
Insights Imaging; 2021 Mar; 12(1):36. PubMed ID: 33738548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
